Anticancer activity and molecular mechanisms of α‐conidendrin, a polyphenolic compound present in Taxus yunnanensis, on human breast cancer cell lines

Abstract

α-Conidendrin is a polyphenolic compound found mainly in Taxus yunnanensis, as the source of chemotherapy drug paclitaxel, which has been used in traditional medicine for treatment of cancer. This study aimed to investigate the anticancer activity and molecular mechanisms of α-conidendrin on breast cancer cell lines. The results of the present study show that α-conidendrin possesses potent antiproliferative effects on breast cancer cell lines MCF-7 and MDA-MB-231. α-Conidendrin significantly induced apoptosis in breast cancer cells via reactive oxygen species generation, upregulation of p53 and Bax, downregulation of Bcl-2, depolarization of mitochondrial membrane potential (MMP), release of cytochrome c from mitochondria, and activation of caspases-3 and -9. α-Conidendrin remarkably inhibited the proliferation of breast cancer cells through induction of cell cycle arrest by upregulating p53 and p21 and downregulating cyclin D1 and CDK4. Unlike breast cancer cells, the antiproliferative effect of α-conidendrin on human foreskin fibroblast cells (normal cells) was very small. In normal cells, reactive oxygen species levels, loss of MMP, release of cytochrome c, mRNA expression of p53, p21, cyclin D1, CDK4, Bax, and Bcl-2 as well as mRNA expression and activity of caspases-3 and -9 were significantly less affected by α-conidendrin compared with cancer cells. These results suggest that α-conidendrin can be a promising agent for treatment of breast cancer with little or no toxicity against normal cells. K E Y W O R D S apoptosis, breast cancer, cell cycle, polyphenolic compound, α-conidendrin

Promising Strategy of mPTP Modulation in Cancer Therapy: An Emerging Progress and Future Insight

“…The therapeutic regime using amorfrutin C shows considerable disruption of mitochondrial integrity, which results in an irreversible opening of mPTP in HT-29 cells [ 44 ]. There is increasing recognition of other nutraceuticals such as allyl isothiocyanate [ 212 ], α-conidendrin [ 213 ], dehydrobruceine B [ 214 ], frugoside [ 215 ], methyl caffeate [ 216 ], tetrahydrocurcumin [ 217 ], phloretin [ 218 ], and sesamol [ 219 ] for their anticancer capacities. These nutraceuticals demonstrate anticancer capacities through disruption of mitochondria through ROS production, Cyt C release, loss of mitochondrial membrane potential, and modulation of Bcl-2 family members, ultimately leading to mPTP opening and inducing cell apoptosis.…”

Curcumin Nanoparticles as Promising Therapeutic Agents for Drug Targets

“…Nanocurcumin was found to decrease the cytokine levels and as a result decreased the mortality and severity in patients with COVID-19. Hence, nanocurcumin has been suggested as a potential therapeutic agent in controlling inflammation or inflammatory diseases due to its anti-inflammatory and immune-modulatory properties [ 104 ]. Moreover, curcumin when loaded in solid-lipid nanoparticles have been found to be effective in treating LPS-induced sepsis by modulating the inflammatory pathways such as TLR4/2-NF-kB.…”

The anticarcinogenic and anticancer effects of the dietary flavonoid, morin: Current status, challenges, and future perspectives

“…ROS have been found to function as second messengers in the regulation of a variety of cellular processes such as cell proliferation, differentiation, and migration (Perillo et al, 2020; Redza‐Dutordoir & Averill‐Bates, 2016). Studies have indicated that ROS generation at high levels can be associated with the activation of cell death signaling pathways such as apoptosis (Hafezi, Hemmati, Abbaszadeh, Valizadeh, & Makvandi, 2020). It is well documented that ROS activate both the intrinsic mitochondrial and the extrinsic death receptor pathways of apoptosis (Perillo et al, 2020; Redza‐Dutordoir & Averill‐Bates, 2016).…”

“…Shin et al (2017) associated with the activation of cell death signaling pathways such as apoptosis(Hafezi, Hemmati, Abbaszadeh, Valizadeh, & Makvandi, 2020). It is well documented that ROS activate both the intrinsic mitochondrial and the extrinsic death receptor pathways of apoptosis(Perillo et al, 2020;Redza-Dutordoir & Averill-Bates, 2016).…”